Morgan Stanley Maintains Equal-Weight on Haemonetics, Raises Price Target to $88
Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $84 to $88.
Earnings Scheduled For February 7, 2023
Companies Reporting Before The Bell
• BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.
9 Analysts Have This to Say About Haemonetics
Analysts have provided the following ratings for Haemonetics (NYSE:HAE) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $92
Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the price target from $88 to $92.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 108 stocks hit new 52-week highs.
Analysts Take Bullish Stance On Haemonetics, Cites Plasma Momentum As Catalyst
JMP Securities raised the price target to $105 from $90 on Haemonetics Corporation (NYSE:HAE) with a Market Outperform rating following the release of…
Mizuho Maintains Buy on Haemonetics, Raises Price Target to $100
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $90 to $100.
JMP Securities Maintains Market Outperform on Haemonetics, Raises Price Target to $105
JMP Securities analyst David Turkaly maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $90 to $105.
Raymond James Maintains Outperform on Haemonetics, Raises Price Target to $100
Raymond James analyst Andrew Cooper maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $88 to $100.
Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $88
Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the price target from $80 to $88.